We used the well-studied CpDV-IL2-sPD1/MS DNA vaccine, which encodes two tumor antigens, MUC1 (M) and survivin (S), and included soluble PD1, CpG motif, and IL-2 as immunoadjuvants to enhance the CD8+ T cell-mediated antitumor immune response. Here, CD8A is linked to neoplasm.